news
Preventing fungal contamination in pharmaceuticals
While fungal contamination detection in pharmaceutical manufacturing remains a challenge, preventive practices and policies must be followed, research states.
List view / Grid view
fungal infections
news
Innovative mass spectrometry method facilitates accurate C. auris identification
A novel high resolution mass spectrometer can accurately identify one of most common nosocomial fungal pathogens, researchers have found.
article
How can evidence-based medicine (EBM) methodology support drug withdrawals?
In this article, Samantha Lane of the UK’s Drug Safety Research Unit discusses the development of an evidence-based medicine (EBM) methodology to assess the positive impact of withdrawing or revoking licences for medicines on public health. The approach leverages electronic health records to model the estimated number of adverse reactions…
article
Improvements in skin and nail drug delivery using nano formulations
It might be easy to dismiss non-life-threatening diseases of the skin or nail as trivial, but their impact on physical and mental wellbeing can be significant. Such diseases are obvious targets for topical treatments, but the lack of effective formulations means patients are often faced with the prospect of oral…
news
Novel blood cleansing device to enter first-in-human trial
The Garnet™ therapeutic product, which can capture more than 100 clinically relevant bacteria, fungi, parasites, toxins and viruses from the blood, will soon begin clinical testing.
news
‘Cocktail’ of pharmaceuticals identified in Bangladeshi waters
A study of both city and rural water sources identified antimicrobials at every site and suggests the contamination could be causing the emergence of treatment-resistant microbes.
news
Phase Ib study for oral Amphotericin B meets primary endpoints
A Phase Ib trial for the study of the oral formulation for Amphotericin B has met its primary endpoints, demonstrating safety in patients.
news
Fast Track designation granted to fosmanogepix for seven indications
Both the intravenous and oral formulations of the antifungal candidate, fosmanogepix, have been granted Fast Track designation by the FDA.
